PPIDT00041
Drug Information
| Name | Insulin lispro |
|---|---|
| Sequence | GIVEQCCTSICSLYQLENYCN |
| DrugBank_ID | DB00046 |
| Type | biotech |
| Indication | Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.[L47616] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous; Subcutaneous |
100 U/1mL
|
| Injection, solution | Subcutaneous |
100 U/1mL
|
| Solution | Subcutaneous |
100 unit / mL
|
| Solution | Intravenous; Subcutaneous |
10000000 U
|
| Injection, solution | — |
40 U/ML
|
| Injection, solution | Intramuscular; Parenteral; Subcutaneous |
100 U/ML
|
| Injection, solution | Intramuscular; Parenteral; Subcutaneous |
200 U/ML
|
| Injection, solution | Intravenous |
100 U/ML
|
| Injection, solution | Intravenous; Subcutaneous |
100 U/ML
|
| Injection, solution | Intravenous; Subcutaneous |
100 [iU]/1mL
|
| Injection, solution | Subcutaneous |
100 [iU]/1mL
|
| Injection, solution | Subcutaneous |
200 U/ML
|
| Injection, suspension | Intramuscular; Parenteral; Subcutaneous |
100 U/ML
|
| Injection, suspension | Parenteral; Subcutaneous |
100 IU/ml
|
| Injection, suspension | Parenteral; Subcutaneous |
100 U/ML
|
| Injection, suspension | Subcutaneous |
100
|
| Solution | — |
100 iu/1ml
|
| Solution | Subcutaneous |
100 U/ml
|
| Solution | Subcutaneous |
100 UI
|
| Solution | Intramuscular; Intravenous; Subcutaneous |
100 unit / mL
|
| Suspension | Parenteral |
350000 mg
|
| Solution | Subcutaneous |
100 iu/ml
|
| Solution | Intravenous; Subcutaneous |
350000 mg
|
| Solution | Subcutaneous |
200 unit / mL
|
| Injection | Subcutaneous |
100 iu/ml
|
| Injection, solution | Intravenous; Subcutaneous |
100 iu/1ml
|
| Injection, solution | Subcutaneous |
200 [iU]/1mL
|
| Injection | Intravenous; Subcutaneous |
100 iu/ml
|
| Injection | Subcutaneous |
200 U/mL
|
| Solution | Subcutaneous |
20000000 U
|
| Suspension | — |
100 iu/1ml
|
| Suspension | Subcutaneous |
|
| Injection, suspension | Subcutaneous |
100 IU/mL
|
| Injection, suspension | Subcutaneous |
100 U/mL
|
| Injection, suspension | — |
100 iu/1ml
|
| Injection | Subcutaneous |
|
| Injection; injection, suspension | Subcutaneous |
100 IU/ML
|
| Injection, suspension | Subcutaneous |
100 [iU]/1mL
|
| Liquid | Intramuscular; Intravenous; Subcutaneous |
100 unit / mL
|
| Injection, solution | Intramuscular; Subcutaneous |
100 U/ML
|
| Injection, solution | Parenteral; Subcutaneous |
100 U/ML
|
| Injection, solution | — |
100 U/ml
|
| Injection, solution | — |
200 U/ml
|
| Injection, solution | Subcutaneous |
100 U/ML
|
| Solution | Intravenous; Subcutaneous |
100 unit / mL
|
| Solution | Intravenous; Subcutaneous |
300 unit / 3 mL
|
| Solution | Subcutaneous |
200 U
|
| Solution | Subcutaneous |
600 unit / 3 mL
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P06213 | INSR | Insulin receptor | Homo sapiens | agonist | Link |
| target | P08069 | IGF1R | Insulin-like growth factor 1 receptor | Homo sapiens | activator | Link |
| enzyme | P05177 | CYP1A2 | Cytochrome P450 1A2 | Homo sapiens | inducer | Link |
| enzyme | P14735 | IDE | Insulin-degrading enzyme | Homo sapiens | substrate | Link |